Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-14T09:34:09.780Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism: are we ready?

Published online by Cambridge University Press:  04 March 2015

Martin Kuuskne  and
Jerrald Dankoff
Martin Kuuskne*
Affiliation:
Department of Emergency Medicine, Royal Victoria Hospital
Jerrald Dankoff
Affiliation:
Department of Emergency Medicine, Jewish General Hospital, Montreal, QC
*
Department of Emergency Medicine, Royal Victoria Hospital, 687 Pine Avenue West, A4.62, Montreal, QC H3A 1A1; martin.kuuskne@mail.mcgill.ca

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

noninferiority trialpulmonary embolismrivaroxaban
Type
Knowledge To Practice • Des connaissances à la pratique
Information
Canadian Journal of Emergency Medicine , Volume 16 , Issue 2 , March 2014 , pp. 155 - 157
Copyright
Copyright © Canadian Association of Emergency Physicians 2014

References

REFERENCES

1. Silverstein, MD, Heit, JA, Mohr, DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–93, doi:10.1001/archinte.158.6.585.Google Scholar
2. Douketis, JD, Kearon, C, Bates, S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458–62, doi:10.1001/jama.279.6.458.Google Scholar
3. Bauersachs, R, Berkowitz, SD, Brenner, B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. NEngl J Med 2010;363:2499–510, doi:10.1056/NEJMoa1007903.Google Scholar
4. Eriksson, BI, Dahl, OE, Rosencher, N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–85, doi:10.1111/j.1538-7836.2007.02748.x.Google Scholar
5. Eriksson, BI, Dahl, OE, Rosencher, N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007;370:949–56, doi:10.1016/S0140-6736(07)61445-7.Google Scholar
6. Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEngl J Med 2009;361:2342–52, doi:10.1056/NEJMoa0906598.CrossRefGoogle ScholarPubMed
7. Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51, doi:10.1056/NEJMoa0905561.CrossRefGoogle ScholarPubMed
8. Eerenberg, ES, Kamphuisen, PW, Sijpken, MK, et al. Reversal of rivaroxaban and dabgatran by prothrombin complex concentrate; a randomized, placebo-controlled, crossover study in healthy patients. Circulation 2011;124:1573–9, doi:10.1161/CIRCULATIONAHA.111.029017.Google Scholar
9. Lee, S, Anglade, M, Pisacane, R, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prophylaxis in atrial fibrillation. Am J Cardiol 2012;110:845–51.Google Scholar